Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.53 |
| ▸ | MMP9 | P14780 | 4/20 | 0.53 |
| ▸ | MMP8 | P22894 | 4/20 | 0.53 |
| ▸ | MMP13 | P45452 | 4/20 | 0.53 |
| ▸ | BTK | Q06187 | 4/20 | 0.52 |
| ▸ | BLK | P51451 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NR2E3 | Q9Y5X4 | 2/20 | 0.51 |
| ▸ | COMT | P21964 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 3/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1136409 | 0.96 | BLK (0.57) | MMP2MMP9MMP8MMP13BTK | |
| SCHEMBL1136398 | 0.94 | BTK (0.59) | MMP2MMP9MMP8MMP13BTK | |
| SCHEMBL4487422 | 0.88 | MMP2 (0.58) | MMP2MMP9MMP8MMP13KDM4E | |
| SCHEMBL1136397 | 0.88 | NR2E3 (0.61) | MMP2MMP9MMP8MMP13KDM4E | |
| SCHEMBL1136389 | 0.87 | DGAT1 (0.54) | BTKBLKKDM4EMAPTHPGD | |
| SCHEMBL1136423 | 0.87 | CHEK2 (0.52) | MMP2MMP9MMP8MMP13BTK | |
| SCHEMBL1136406 | 0.87 | BLK (0.48) | MMP2MMP9MMP8MMP13BTK | |
| SCHEMBL1136433 | 0.86 | BTK (0.57) | MMP2MMP9MMP13BTKBLK | |
| SCHEMBL1136434 | 0.86 | BTK (0.57) | MMP2MMP9MMP13BTKBLK | |
| SCHEMBL5306882 | 0.86 | MMP2 (0.66) | MMP2MMP9MMP8MMP13MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919910-B1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | claimed |
| CN-101208338-B | Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents | HOFFMANN LA ROCHE | 2010-12-29 | — | — | CN | claimed |
| US-20090227578-A1 | Azabenzimidazole Derivatives, Their Manufacture and Use as Anti-Cancer Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | claimed |
| CN-101208338-A | Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | claimed |
| EP-1919910-A1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | F. Hoffmann-la Roche AG (CH) | 2008-05-14 | — | — | EP | claimed |
| WO-2007017143-A1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | claimed |
| EP-1919910-B1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| CN-101208338-B | Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents | HOFFMANN LA ROCHE | 2010-12-29 | — | — | CN | disclosed |
| US-20090227578-A1 | Azabenzimidazole Derivatives, Their Manufacture and Use as Anti-Cancer Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | disclosed |
| CN-101208338-A | Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227578-A1 | Azabenzimidazole Derivatives, Their Manufacture and Use as Anti-Cancer Agents | AZI2, CDKN1A, CCNI | MMP2 1903/4885MMP9 1480/4885MMP8 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.